The retail price of Zepbound without insurance is real — but almost no one without insurance pays it. There are four distinct pathways to tirzepatide for patients without coverage in 2026, ranging from $50/month to $599/month. This guide covers all four, what they require, what the actual costs are at each dose, and which path makes sense based on your situation.
🟢 July 1, 2026: Medicare GLP-1 Bridge is now live
Eligible Medicare Part D beneficiaries can now access Zepbound (KwikPen only) for $50/month through the Bridge program. Prior authorization required — submitted to the CMS Bridge processor, not your Part D plan.
Full enrollment guide →
Zepbound price at every dose — without insurance, July 2026
| Dose | Retail (pharmacy) | Lilly Direct | Compounded equiv. | Medicare Bridge |
|---|
| 2.5mg/week | ~$499/mo | $349/mo | $150–$280/mo | $50/mo ✓ |
| 5mg/week | ~$499/mo | $349/mo | $200–$320/mo | $50/mo ✓ |
| 7.5mg/week | ~$549/mo | $349/mo | $250–$360/mo | $50/mo ✓ |
| 10mg/week | ~$549/mo | $349/mo | $280–$380/mo | $50/mo ✓ |
| 12.5mg/week | ~$599/mo | $349/mo | $320–$397/mo | $50/mo ✓ |
| 15mg/week | ~$599/mo | $349/mo | $350–$397/mo | $50/mo ✓ |
Key finding: Lilly Direct costs the same $349/month regardless of dose — making it meaningfully cheaper than retail at higher doses. Compounded tirzepatide is cheapest at lower doses and becomes comparable to Lilly Direct at the 12.5–15mg maintenance dose.
Every real option — ranked by cost
Compounded tirzepatide from licensed 503A compounding pharmacies is the most accessible and typically most affordable path to tirzepatide without insurance. The active pharmaceutical ingredient is the same molecule as Zepbound — tirzepatide — prepared by licensed pharmacists at state-regulated compounding facilities. You receive vials and syringes rather than Eli Lilly's proprietary auto-injector pen.
Telehealth platforms handle the physician consultation, prescription, and pharmacy coordination in one workflow. Most process intake within 24-48 hours. DirectMeds offers compounded tirzepatide from $397/month all-inclusive with no membership fee.
Advantages
- Lowest monthly cost, especially at lower doses
- Physician consultation included
- No insurance required
- Ships to 48 states
- Same tirzepatide molecule as Zepbound
Considerations
- Requires self-injection with syringe (no auto-pen)
- Not FDA-approved as finished product
- Must verify pharmacy is licensed 503A
- Supply subject to FDA compounding policy changes
For eligible Medicare beneficiaries, the Bridge launched July 1, 2026 covers brand-name Zepbound KwikPen at a $50/month copay — the most affordable access to Zepbound available anywhere. The $50 does not count toward your Part D deductible or $2,100 annual out-of-pocket maximum.
Eligibility: Medicare Part D coverage + BMI ≥35, or BMI ≥30 with hypertension/kidney disease/heart failure, or BMI ≥27 with prediabetes/cardiovascular disease. Prior authorization required — submitted to the CMS Bridge processor (not your Part D plan). Covers Zepbound KwikPen only — vials and single-dose pens are excluded.
Advantages
- Lowest possible cost — $50/month
- Brand-name Zepbound KwikPen
- FDA-approved finished product
- Auto-injector pen, no syringe required
- Runs through December 31, 2027
Considerations
- Medicare Part D required — not for under-65
- BMI and condition eligibility criteria
- Prior auth takes up to 72 hours
- Bridge expires Dec 31, 2027
Lilly Direct is Eli Lilly's own savings program for uninsured patients. At $349/month for any dose, it's meaningfully cheaper than retail — especially at higher doses where retail hits $599/month. You access brand-name Zepbound with the KwikPen auto-injector and the full FDA manufacturing standards.
Enrollment requires a valid prescription from a licensed physician and proof of no insurance coverage for tirzepatide. Available at lillydirect.com. Not available if you have commercial insurance that covers Zepbound, Medicare, or Medicaid.
Advantages
- Brand Zepbound — FDA-approved finished product
- KwikPen auto-injector
- One price for all doses — flat $349
- Direct from manufacturer
Considerations
- Requires separate physician visit/prescription
- More expensive than compounded at lower doses
- Not available with any insurance coverage
- Program terms subject to Lilly policy changes
The standard retail price at major pharmacy chains without any savings program. This is what you pay if you present a Zepbound prescription without Lilly Direct enrollment, insurance coverage, or any discount program. At $499–$599/month, this is rarely the right option — Lilly Direct costs $150–$250 less per month for the identical product.
Does GoodRx help? For Zepbound specifically, GoodRx and most third-party discount cards provide minimal savings compared to Lilly Direct. Eli Lilly's manufacturer terms restrict the discount card pricing channel for Zepbound. Check Lilly Direct before relying on any discount card.
Advantages
- Brand Zepbound, KwikPen
- No program enrollment required
- Immediate pickup at pharmacy
Considerations
- Highest cost of all options
- No advantage over Lilly Direct
- GoodRx doesn't help meaningfully
Get compounded tirzepatide from $397/month
DirectMeds offers physician-supervised compounded tirzepatide — same active molecule as Zepbound — with no membership fee and same-day eligibility check.
Check eligibility at DirectMeds →
Sponsored · From $397/month tirzepatide · No membership fee · 48 states
Compounded tirzepatide vs brand Zepbound — what's actually different
This is the question most uninsured patients actually need answered. The short version: same molecule, different manufacturer, different regulatory status, different price.
| Factor | Compounded tirzepatide | Brand Zepbound |
|---|
| Active ingredient | Tirzepatide (identical) | Tirzepatide |
| Mechanism of action | Identical GLP-1/GIP dual agonist | Identical GLP-1/GIP dual agonist |
| Expected weight loss | Same clinical mechanism | 22% avg at 72 weeks (SURMOUNT-1) |
| FDA approval | Not approved as finished product | FDA-approved (tirzepatide) |
| Delivery format | Vial + syringe (self-draw) | KwikPen auto-injector |
| Pharmacy oversight | State board + USP 795/797 | FDA manufacturing standards |
| Monthly cost (uninsured) | $150–$397 | $349–$599 |
| Physician consultation | Included (telehealth) | Separate visit required |
The practical answer: If you're willing to self-inject with a syringe and comfortable with licensed-but-not-FDA-approved compounded medications, compounded tirzepatide at $150–$397/month is clinically equivalent and meaningfully cheaper. If you want the Eli Lilly KwikPen and full FDA manufacturing assurance, Lilly Direct at $349/month is the right choice — not retail at $499–$599.
What to watch in 2026 — FDA compounding policy
The FDA's compounding policy for tirzepatide has been in flux. During the Zepbound shortage period, compounding was broadly permitted. As Zepbound supply normalized, FDA began enforcement actions against some compounders in late 2025. In early 2026, a federal court ruling paused FDA's enforcement, allowing compounding to continue through the appeals process.
The situation as of July 2026: compounded tirzepatide remains available through licensed 503A pharmacies and reputable telehealth platforms. However, the regulatory environment is more uncertain than it was in 2024-2025. Patients starting tirzepatide should be aware that compounding policy could change, and have a plan for transitioning to Lilly Direct or brand Zepbound if compounding access changes.
How to protect yourself: Only use telehealth platforms working with licensed 503A compounding pharmacies (not 503B — different regulatory category). Verify LegitScript certification. Request a Certificate of Analysis for your medication. Have a Lilly Direct account set up as a backup, even if you don't use it immediately.
How to qualify for Zepbound — eligibility requirements
Whether accessing brand Zepbound or compounded tirzepatide, clinical eligibility requirements are largely consistent across programs:
- BMI ≥30 — standard threshold for GLP-1 weight management indication
- BMI ≥27 with weight-related health condition — high blood pressure, type 2 diabetes, high cholesterol, sleep apnea, or cardiovascular disease qualifies you at a lower BMI
- No personal or family history of medullary thyroid carcinoma or MEN2 — absolute contraindication for all GLP-1 medications
- No active pancreatitis
- Age 18+ for weight management indication
Telehealth platforms conduct their own eligibility screening during intake. Physician consultation is standard before any prescription is issued.
Frequently asked questions
How much is Zepbound without insurance?
Zepbound without insurance costs $499–$599/month at retail pharmacy, depending on dose. Through Lilly Direct (manufacturer savings), it's $349/month for any dose. Compounded tirzepatide through telehealth runs $150–$397/month. Medicare beneficiaries who qualify for the GLP-1 Bridge pay $50/month as of July 1, 2026.
What is the cheapest way to get Zepbound without insurance?
The cheapest way is compounded tirzepatide through a licensed telehealth platform — $150–$397/month depending on dose and provider. For Medicare beneficiaries who qualify, the GLP-1 Bridge offers Zepbound KwikPen at $50/month copay. For brand Zepbound specifically, Lilly Direct at $349/month is cheapest — not retail pharmacy.
How much is Zepbound 5mg without insurance?
Zepbound 5mg without insurance costs approximately $499/month at retail. Through Lilly Direct: $349/month. Through telehealth compounding: $200–$320/month for equivalent compounded tirzepatide at 5mg. Medicare Bridge (if eligible): $50/month copay.
Is compounded tirzepatide as effective as Zepbound?
Compounded tirzepatide contains the same active pharmaceutical ingredient (tirzepatide) as Zepbound and follows the same titration protocol. The clinical mechanism is identical. Differences: Zepbound is FDA-approved as a finished product from Eli Lilly; compounded versions are prepared by licensed 503A compounding pharmacies under state oversight. The expected weight loss outcomes are the same — the molecule is identical.
Can Medicare pay for Zepbound?
As of July 1, 2026, yes — through the Medicare GLP-1 Bridge program. Eligible Medicare Part D beneficiaries can access Zepbound KwikPen at a $50/month copay. Eligibility requires BMI 35+ or BMI 30+ with qualifying conditions. Prior authorization is required. The Bridge runs through December 31, 2027. Standard Medicare outside this Bridge program does not cover GLP-1 medications for weight loss.
Does GoodRx work for Zepbound?
GoodRx and most discount cards provide minimal savings on Zepbound compared to Lilly Direct. Eli Lilly's manufacturer terms with pharmacies restrict discount card pricing for Zepbound. Check Lilly Direct at lillydirect.com before using any third-party discount card — Lilly Direct will typically be cheaper.
What is the monthly cost of Zepbound without insurance?
Monthly cost without insurance by channel: retail pharmacy $499–$599 (dose-dependent); Lilly Direct manufacturer program $349 (any dose); compounded tirzepatide $150–$397; Medicare GLP-1 Bridge $50 (if eligible). Annual cost at retail: $6,000–$7,200. Annual cost via Lilly Direct: $4,188. Annual cost via compounded: $1,800–$4,764.
How can I get Zepbound without insurance?
Four pathways: (1) Compounded tirzepatide via telehealth — $150–$397/month, physician consultation included, most accessible; (2) Medicare GLP-1 Bridge — $50/month for eligible Medicare beneficiaries as of July 1, 2026; (3) Lilly Direct — brand Zepbound at $349/month, requires physician prescription and proof of no coverage; (4) Retail pharmacy — $499–$599/month, not recommended when Lilly Direct is available for less.
How much is tirzepatide without insurance?
Brand-name tirzepatide (Zepbound) costs $499–$599/month retail or $349/month via Lilly Direct. Compounded tirzepatide (same active molecule) costs $150–$397/month through telehealth platforms. The cost difference between brand and compounded is $100–$400/month, with compounded being cheapest at lower doses and comparable to Lilly Direct at 12.5–15mg.
Sources & references
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216. PMID:35658024 — Source for 22% average weight loss with tirzepatide at 72 weeks.
- Eli Lilly and Company. Lilly Direct pricing for Zepbound (tirzepatide) injection. lillydirect.com — Source for $349/month manufacturer savings pricing, verified July 2026.
- Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge Program — Coverage and Enrollment. cms.gov — Source for Bridge launch date (July 1, 2026), $50 copay, BIN 028918, eligibility criteria.
- FDA. Outsourcing Facilities and Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act. fda.gov — Source for 503A/503B compounding regulatory framework.
Medical disclaimer: Informational only. Not medical advice. Consult a licensed physician before starting any medication.
Price disclaimer: Prices verified July 2026 against manufacturer, pharmacy, and telehealth platform sources. Prices subject to change. Verify current pricing directly with the relevant program or provider.